Company Encyclopedia
View More
name
UNITED LAB
03933.HK
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin products, nervous system drugs, vitamins, veterinary drugs, and vacant gelatin capsules. It also provides intermediate products, such as 6-aminopenicillanic acid, tert-octylammonium clavulanate, anhydrous sodium carbonate sterile, and penicillin G potassium first crystal.
1.450 T
03933.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking20/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE21.05%A
    • Profit Margin21.72%A
    • Gross Margin52.19%B
  • Growth ScoreC
    • Revenue YoY0.81%C
    • Net Profit YoY5.47%C
    • Total Assets YoY31.35%A
    • Net Assets YoY17.16%A
  • Cash ScoreC
    • Cash Flow Margin460.45%C
    • OCF YoY0.81%C
  • Operating ScoreC
    • Turnover0.54C
  • Debt ScoreC
    • Gearing Ratio46.96%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | UNITED LAB (3933.HK) shows weakness in intraday trading, is the marginal signal of sector sentiment worth tracking?

    UNITED LAB (3933.HK) faced downward pressure yesterday, with funds tentatively flowing out after the opening, and multiple attempts to hold the HKD 8.5 range during the day. The company has had no new positive news for three days, and the sentiment in the pharmaceutical sector is low, with scattered buying. The MACD shows a slight death cross and is under pressure from moving averages. Attention should be paid to whether there is an unusual large inflow of funds at support points. If support is lost in the short term, there may be a risk of structural overselling, and any unusual movements should be verified in conjunction with the overall sentiment of the sector

    Technical Forecast·
    HK
    03933
    -0.31%
    Technical Forecast·
    HK
    03933
    -0.31%

    China Post Securities: Initiates "Buy" rating on UNITED LAB, insulin formulation business performs impressively

    China Post Securities has initiated coverage on UNITED LAB, giving it a "Buy" rating. It is expected that the company will launch 6 new products or indications between 2025 and 2027, with revenues of 13.42 billion, 12.65 billion, and 13.84 billion yuan, respectively. In the first half of 2025, the company achieved revenue of 7.52 billion yuan, with EBITDA of 2.75 billion yuan and net profit attributable to the parent company of 1.89 billion yuan. The insulin formulation business performed outstandingly, with revenue growth of 74.5%

    Zhitong·
    HK
    03933
    -0.31%
    Zhitong·
    HK
    03933
    -0.31%

    UNITED LAB will distribute a mid-term dividend of HKD 0.17507 per share on October 15

    According to the Zhitong Finance APP, UNITED LAB announced that it will distribute a mid-term dividend of HKD 0.17507 per share for the six months ending June 30, 2025, on October 15, 2025

    Zhitong·
    HK
    03933
    -0.31%
    Zhitong·
    HK
    03933
    -0.31%

    UNITED LAB: Injection UBT37034 for overweight or obesity indications has received clinical trial implied approval

    UNITED LAB announced that its wholly-owned subsidiary, UNITED BIOTECH (Zhuhai Hengqin) Co., Ltd., has obtained the implied approval from the National Medical Products Administration of China for the clinical trial of UBT37034 injection targeting overweight or obesity. This drug is a novel peptide receptor agonist that can reduce weight by selectively acting on the neuropeptide Y2 receptor. The clinical trial application for UBT37034 was approved by the U.S. FDA in July 2025. The company will continue to focus on the research and development of new products to enhance its competitiveness in the biopharmaceutical industry

    Zhitong·
    HK
    03933
    -0.31%
    Zhitong·
    HK
    03933
    -0.31%

    Zhongtai Securities: Initiates coverage on UNITED LAB with a "Buy" rating, indicating a broad space for innovative pipelines

    Zhongtai Securities has initiated coverage on UNITED LAB with a "Buy" rating. It is expected that the revenue for 2025-2027 will be 15.088 billion, 14.651 billion, and 16.036 billion yuan, respectively, with net profit attributable to the parent company at 2.758 billion, 2.638 billion, and 2.956 billion yuan. The company has a broad innovation pipeline, stable traditional business, and continuous growth in insulin preparations and animal health business, driving its transformation into an innovative drug company for metabolic diseases. The significant licensing of UBT251 demonstrates its R&D strength

    Zhitong·
    HK
    03933
    -0.31%
    Zhitong·
    HK
    03933
    -0.31%
    © 2025 Longbridge｜Disclaimer